Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Could Achieve Gains In The Near Future

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

Amneal Pharmaceuticals Inc is listed on the NASDAQ in the Healthcare sector while operating in the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Amneal Pharmaceuticals Inc is $1.69B. A total of 1.33 million shares were traded on the day, compared to an average of 1.36M shares.

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, AMRX has seen 1 BUY and 0 SELL insider trades, representing the acquisition of 53,578,209 and the disposition of 0 shares. Over the last 12 months, there were 23 BUYs and 11 SELLs from insiders. Insiders purchased 54,748,347 shares during that period but sold 169,121.

In the most recent transaction, BOYER ANDREW S sold 29,302 shares of AMRX for 4.13 per share on Aug 11. After the transaction, the Executive Vice President now owns 244,739 company shares.

Dividend

The reasons why investors prefer dividend-paying companies are that dividends generate immediate cash flow and indicate that the company will perform well in the future. Amneal Pharmaceuticals Inc pays an annual dividend of $0.01, resulting in a dividend yield of 0.27%, and it has a price to earnings (P/E) ratio of 87.05.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for AMRX in the last 3 months, the mean price target is $6.63 with high estimates of $8.00 and low estimates of $5.50. In terms of 52-week highs and lows, AMRX has a high of $6.30 and a low of $1.24.

As of this writing, AMRX has an earnings estimate of $Amarin Corporation plc per share for the current quarter. EPS was calculated based on a consensus of AMLX estimates, with a high estimate of $Alpha Metallurgical Resources, per share and a lower estimate of $Aemetis, Inc.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AMRX is Buy with a score of 4.20.

Most Popular

Related Posts